Posted by Michael Wonder on 05 Jul 2018
Vertex calls NHS England ‘outrageous’ as Orkambi talks stall again
5 July 2018 - Public row about confidential pricing talks drags on.
Negotiations between Vertex and NHS England on a pricing and access deal for the cystic fibrosis drug Orkambi have stalled once again, with the pharma company hitting out at the payer’s approach.
However the truth of who, if anyone, is being unreasonable in the talks is impossible to make out - as the negotiations and the pricing offer on the table remain strictly confidential.
